Copyright © Inderes 2011 - present. All rights reserved.
  • Seneste
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Udbyttekalender
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team
Selskabsmeddelelse

Vitrolife AB (publ): Interim report January-March 2022: Building on our strong growth momentum

Vitrolife
Download udgivelse
First quarter
  • Sales of SEK 752 (379) million, corresponding to an increase of 98% in SEK whereof currency effect 13%, acquired growth 74% and organic growth 11%.
  • Consumables increased sales by 26% in SEK, Technologies by 4% in SEK, and Genetic Services contributed with sales of SEK 304 million.
  • Strong growth in all market regions: Americas 255%, EMEA 85%, Japan Pacific 21% and Asia 19% in local currencies.
  • Operating income before depreciation and amortisation (EBITDA) was SEK 228 (163) million, corresponding to a margin of 30.4% (43.0). EBITDA per share increased 13%.
  • Net income was SEK 82 (119) million, resulting in earnings per share of SEK 0.60 (1.09).
Pro forma
  • Sales, adjusted for discontinuing Covid business, increased by 18% in SEK, and 11% in local currencies.
  • EBITDA margin of 30.4% (34.4%).

Gothenburg, April 22, 2022
VITROLIFE AB (publ)
Thomas Axelsson, CEO

Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.